iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting
1
18
US
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Neuroblastoma, Osteosarcoma
05/25
06/39
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
02/25
02/27

Download Options